This study investigates the relationship between the systemic immune-inflammation index (SII) and all-cause mortality (ACM) risk in individuals with stages IIIB–IV epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.